Citrate synthase

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Retrieved on:

Venerdì, Marzo 22, 2024

ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions for the label update of both bempedoic acid (marketed as NILEMDO®▼) and the bempedoic acid / ezetimibe fixed dose combination (FDC) (marketed as NUSTENDI®▼ ), recommending their approval as treatments to reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.2 The existing label of bempedoic acid (NILEMDO®▼) provides authorisation for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2

Key Points:

“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide,” said Sheldon Koenig, President and CEO, Esperion.
The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Wolters Kluwer CCH Tagetik inTouch Online Conference Inspires CFOs to Evolve NOW with Solutions for Today and for a Future of Accelerated Financial Transformation

Retrieved on:

Martedì, Giugno 23, 2020

Legal research, Chief financial officer, Citrate synthase, CCH, Articles

Targeting today's pressing concerns and the accelerated changes required to adapt, the event showcased the CCH Tagetik Finance Transformation Platform with a spotlight on the launch of key and very timely new expert solutions.

Key Points:

Targeting today's pressing concerns and the accelerated changes required to adapt, the event showcased the CCH Tagetik Finance Transformation Platform with a spotlight on the launch of key and very timely new expert solutions.
Key innovations highlighted CCH Tagetik's targeted investments in advanced technologies to support the CFO's need for enhanced data & analytics.
Also unveiled was the dynamic new CCH Tagetik SmartInsight reporting tool for creating ad-hoc reports and performing analysis "on-the-fly".
"The CCH Tagetik inTouch Online conference was a tremendous opportunity to share how our portfolio continues to evolve enabling finance transformation, and the response was incredibly positive.

Wolters Kluwer CCH Tagetik inTouch Online Conference Inspires CFOs to Evolve NOW with Solutions for Today and for a Future of Accelerated Financial Transformation

Retrieved on:

Martedì, Giugno 23, 2020

Legal research, Chief financial officer, Citrate synthase, CCH, Articles

Targeting today's pressing concerns and the accelerated changes required to adapt, the event showcased the CCH Tagetik Finance Transformation Platform with a spotlight on the launch of key and very timely new expert solutions.

Key Points:

Targeting today's pressing concerns and the accelerated changes required to adapt, the event showcased the CCH Tagetik Finance Transformation Platform with a spotlight on the launch of key and very timely new expert solutions.
Key innovations highlighted CCH Tagetik's targeted investments in advanced technologies to support the CFO's need for enhanced data & analytics.
Also unveiled was the dynamic new CCH Tagetik SmartInsight reporting tool for creating ad-hoc reports and performing analysis "on-the-fly".
"The CCH Tagetik inTouch Online conference was a tremendous opportunity to share how our portfolio continues to evolve enabling finance transformation, and the response was incredibly positive.

Wolters Kluwer Enhances Cloud-based CCH Axcess™ Knowledge Coach Solution with New Knowledge-based Audit Titles

Retrieved on:

Giovedì, Maggio 14, 2020

Professional services, Data management, Technology, Software, Finance, Banking, Accounting, Legal research, Accounting software, CCH, Riverwoods, Illinois, Wolters Kluwer, Citrate synthase, Articles, Publishers, Business

Today, Wolters Kluwer Tax & Accounting announced the addition of new Knowledge-Based Audit Titles to its first CCH Axcess Knowledge Coach audit module on the award-winning CCH Axcess cloud-based tax preparation, compliance and workflow management platform.

Key Points:

Today, Wolters Kluwer Tax & Accounting announced the addition of new Knowledge-Based Audit Titles to its first CCH Axcess Knowledge Coach audit module on the award-winning CCH Axcess cloud-based tax preparation, compliance and workflow management platform.
CCH Axcess Knowledge Coach now features titles for Employee Benefit Plans, Examinations of Service Organizations (SOC), and Common Interest Realty Associations, in addition to the Commercial titles already available.
Providing auditors with the flexibility of anywhere, anytime access, CCH Axcess Knowledge Coach facilitates collaboration across audit engagement, improves overall audit quality, and allows the auditor to exercise professional judgment.
It combines the powerful content-driven tools of CCH ProSystem fx Knowledge Coach and CCH Axcess Knowledge Coach , the efficiency of CCH ProSystem fx Engagement and TeamMate Analytics , plus the comprehensive content of CCH Accounting Research Manager and CCH Axcess Financial Prep , the first dynamic cloud-based trial balance solution integrated with Xero, QBOnline, CCH Axcess Workstream , CCH Axcess Tax , as well as other cloud-based audit solutions soon to be released on the award-winning CCH Axcess platform.